BR112021024845A2 - Combinação para o tratamento de infecções causadas por mycoplasma genitalium - Google Patents
Combinação para o tratamento de infecções causadas por mycoplasma genitaliumInfo
- Publication number
- BR112021024845A2 BR112021024845A2 BR112021024845A BR112021024845A BR112021024845A2 BR 112021024845 A2 BR112021024845 A2 BR 112021024845A2 BR 112021024845 A BR112021024845 A BR 112021024845A BR 112021024845 A BR112021024845 A BR 112021024845A BR 112021024845 A2 BR112021024845 A2 BR 112021024845A2
- Authority
- BR
- Brazil
- Prior art keywords
- infections caused
- mycoplasma genitalium
- treatment
- combination
- genitalium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870990P | 2019-07-05 | 2019-07-05 | |
| US202062985465P | 2020-03-05 | 2020-03-05 | |
| PCT/EP2020/068754 WO2021004910A1 (en) | 2019-07-05 | 2020-07-03 | Combination for the treatment of infections caused by mycoplasma genitalium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024845A2 true BR112021024845A2 (pt) | 2022-01-18 |
Family
ID=71579551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024845A BR112021024845A2 (pt) | 2019-07-05 | 2020-07-03 | Combinação para o tratamento de infecções causadas por mycoplasma genitalium |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220257615A1 (https=) |
| EP (1) | EP3993796B1 (https=) |
| JP (1) | JP7638263B2 (https=) |
| CN (1) | CN114173789A (https=) |
| BR (1) | BR112021024845A2 (https=) |
| CA (1) | CA3143619A1 (https=) |
| ES (1) | ES2981617T3 (https=) |
| WO (1) | WO2021004910A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11917094B2 (en) * | 2021-02-01 | 2024-02-27 | Aptiv Technologies Limited | Automatic control of smartphone driver mode using ultra-wideband communication |
| EP4288035A1 (en) * | 2021-02-05 | 2023-12-13 | GlaxoSmithKline Intellectual Property Development Limited | Oral solid dose formulations |
| JP2025532252A (ja) | 2022-09-26 | 2025-09-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 処置方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| US9993469B2 (en) | 2013-05-28 | 2018-06-12 | Morphochem Aktiengesellschaft Für Kombinatorishe Chemie | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections |
| US10702521B2 (en) * | 2014-08-22 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones |
| WO2018195098A1 (en) * | 2017-04-17 | 2018-10-25 | Ohio State Innovation Foundation | Type ii topoisomerase inhibitors and methods of making and using thereof |
-
2020
- 2020-07-03 US US17/619,367 patent/US20220257615A1/en not_active Abandoned
- 2020-07-03 EP EP20739585.6A patent/EP3993796B1/en active Active
- 2020-07-03 JP JP2022500047A patent/JP7638263B2/ja active Active
- 2020-07-03 ES ES20739585T patent/ES2981617T3/es active Active
- 2020-07-03 WO PCT/EP2020/068754 patent/WO2021004910A1/en not_active Ceased
- 2020-07-03 BR BR112021024845A patent/BR112021024845A2/pt unknown
- 2020-07-03 CN CN202080049062.5A patent/CN114173789A/zh active Pending
- 2020-07-03 CA CA3143619A patent/CA3143619A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022539583A (ja) | 2022-09-12 |
| JP7638263B2 (ja) | 2025-03-03 |
| EP3993796C0 (en) | 2024-02-21 |
| ES2981617T3 (es) | 2024-10-09 |
| CA3143619A1 (en) | 2021-01-14 |
| WO2021004910A1 (en) | 2021-01-14 |
| US20220257615A1 (en) | 2022-08-18 |
| EP3993796A1 (en) | 2022-05-11 |
| EP3993796B1 (en) | 2024-02-21 |
| CN114173789A (zh) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024845A2 (pt) | Combinação para o tratamento de infecções causadas por mycoplasma genitalium | |
| BR112022005896A2 (pt) | Inibidores da mek para o tratamento de infecções causadas por hantavírus | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| MX2022001541A (es) | Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia. | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| BR112015026258A2 (pt) | composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| BR112021019931A2 (pt) | Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral | |
| BR112021021284A2 (pt) | Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra | |
| BR112021016296A2 (pt) | Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele | |
| BR112015025424A2 (pt) | tratamento de câncer usando terapias de combinação de coenzima q10 | |
| BR112015029367A8 (pt) | combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| BR112023017274A2 (pt) | Vacina contra metapneumovírus humano | |
| BR112021025306A2 (pt) | Medicamento e seu uso para o tratamento de infecções bacterianas envolvendo biofilme | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| MX2022010186A (es) | Neurotoxinas botulinas para uso en terapia. | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112017006005A2 (pt) | composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv. | |
| BRPI0916885B8 (pt) | composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |